Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To investigate the level of mRNA expression of complement C3 and C4 in rat nasal mucosa and to reveal the relationship with the pathogenesis of allergic rhinitis (AR) .
Methods: Twenty healthy SD rats were randomly divided into AR group and control group, 10 rats for each group. Ten rats was sensitized and intranasally challenged by ovalbumin and Al (OH)3 (as supplement) as allergic rhinitis models, and the control group was treated by saline. RT-PCR was performed to investigate the level of mRNA expression of complement C3 and C4 in nasal mucosa of both groups.
Results: C3 and C4 mRNA were detected in both groups. The relative intensity of gene expression was measured. The relative intensity of C3 mRNA expression was 6183+/-1376 in AR group, 4444+/-989 in control group, C4 mRNA was 4398 +/-948 in AR group, and 2771+/-407 in control group. Expression of C3 and C4 in AR group was higher than that of the controls ( P < 0. 05) .
Conclusion: The high level of C3 and C4 mRNA expression in nasal mucosa of rats with allergic rhinitis suggests that C3 and C4 are involved in the immunopathology of allergic rhinitis. The result implies that complement system involved in the rat's allergic rhinitis is possibly activated through the classical pathway.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Sex differences in childhood atopic disease and the role of sex-steroid metabolites.
J Allergy Clin Immunol Pract
September 2025
COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Background: Studies have described sex differences in childhood asthma, allergy, and atopic dermatitis, but the development and clinical phenotype of these differences remain poorly understood.
Objective: To characterize sex differences in atopic disease throughout childhood and study the potential role of sex-steroid metabolites.
Methods: We examined sex differences in asthma, allergy, and atopic dermatitis using longitudinal generalized estimating equation models in the COPSAC (n=411) and COPSAC (n=700) birth cohorts.
Oral immunotherapy in children with allergic diseases: past, present and future.
Minerva Pediatr (Torino)
September 2025
Pediatric Respiratory Unit, Department of Clinical and Experimental Medicine, San Marco Hospital, University of Catania, Catania, Italy.
Allergen immunotherapy (AIT) is the only treatment capable of modifying the natural history of allergic diseases by promoting immune tolerance. Initially developed for respiratory allergies, AIT has expanded to include food allergies, particularly through oral immunotherapy (OIT). This review explores the historical evolution, current applications, and future directions of AIT in pediatric patients.
View Article and Find Full Text PDFCharacteristics and Risk Factors of Pollen-Food Allergy Syndrome in Patients With Hay Fever: A Digital Cross-Sectional Cohort Study Using AllerSearch.
J Investig Allergol Clin Immunol
September 2025
Department of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Background And Objectives: Pollen-food allergy syndrome (PFAS) is a frequent comorbidity in individuals with hay fever. Identifying risk factors and allergen clusters can aid targeted interventions and management strategies. Objective: This study characterizes PFAS in patients with hay fever and identifies associated risk factors using the mobile health platform, AllerSearch.
View Article and Find Full Text PDFAcoustic therapy for allergic rhinitis and chronic rhinosinusitis: modulating microbiome, immunity and well-being.
Front Allergy
August 2025
Department of Surgery, University of Auckland, Auckland, New Zealand.
Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) are common respiratory conditions that significantly impact patient health and contribute to substantial healthcare burdens. While conventional treatments offer symptom relief, many patients continue to experience persistent symptoms, side effects, or resistance to standard therapies. This highlights the growing need for novel, non-invasive, and sustainable therapeutic strategies to manage chronic airway inflammation.
View Article and Find Full Text PDFClinical and Healthcare Cost Characteristics of Severe Asthma Patients with Long-Term Control on Omalizumab: A Comparative Analysis with Patients Who Switched to Other Biologics.
J Asthma Allergy
September 2025
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University Kyoto, Kyoto, Japan.
Background And Purpose: Biologics are crucial for severe asthma treatment, but their high costs pose challenges. Omalizumab (OML) is dosed on the basis of patient-specific factors. The purpose of this study is to clarify the clinical characteristics of severe asthmatics who maintain long-term control on omalizumab including healthcare cost considerations.
View Article and Find Full Text PDF